415 Capital Management

About 415 Capital Management

415 Capital is a specialist medtech venture capital firm with more than €300 million of assets under management across two funds as of December 2024 (Fund I approximately €100 million 2020, Fund II €150 million target with first close announced November 2024), headquartered in Munich (Oberhaching). The firm was founded with Fund I launching in 2018-2020 and a team carrying 25 plus years of medtech investing heritage, operating as an independent partner-owned medtech VC with LPs including the EIF, KfW Capital, Wachstumsfonds Deutschland and family offices.

Investment thesis

415 Capital deploys capital through two funds, targeting clinical-stage medtech venture capital that backs breakthrough and life-saving device companies with capital, clinical expertise and market access. Sector focus spans cardiovascular, neurovascular, neuromodulation, medical robotics and patient monitoring and medical imaging plus AI. Geographic deployment spans Europe, the United States and Israel. The platform combines a cardiovascular and neurovascular medtech specialism with an in-house physician network feeding proprietary clinical insight into deal selection, having funded 50 plus medtech companies over the team's history.

Recent activity

Recent realised exits across the team's history span 25 plus medtech and medical device trade sales and IPOs, with no new 2024-2026 exit individually verified. Recent acquisitions include two clinical-stage cardiovascular companies funded from Fund II (2024-2025), with active portfolio additions including Endovascular Engineering and Laza Medical. The platform continues active deployment of Fund II across the clinical-stage medtech mandate. Detailed buyer names and multiple data available on Pro at €49/month.